Krystal Biotech touts topical gene therapy uptake, plots overseas launches

After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for the rare skin disease dystrophic epidermolysis bullosa (DEB). Now, the company has sights set on two other major markets to support its blockbuster ambitions.